Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 13 entries
Sorted by: Best Match Show Resources per page
Clinical significance of novel subtypes of acute lymphoblastic leukemia in the context of minimal residual disease-directed therapy.

Blood cancer discovery

Jeha S, Choi J, Roberts KG, Pei D, Coustan-Smith E, Inaba H, Rubnitz JE, Ribeiro RC, Gruber TA, Raimondi SC, Karol SE, Qu C, Brady SW, Gu Z, Yang JJ, Cheng C, Downing JR, Evans WE, Relling MV, Campana D, Mullighan CG, Pui CH.
PMID: 34250504
Blood Cancer Discov. 2021 Jul;2(4):326-337. doi: 10.1158/2643-3230.bcd-20-0229.

We evaluate clinical significance of recently identified subtypes of acute lymphoblastic leukemia (ALL) in 598 children treated with minimal residual disease (MRD)-directed therapy. Among the 16 B-ALL and 8 T-ALL subtypes identified by next generation sequencing,

Cite
Jeha S, Choi J, Roberts KG, et al. Clinical significance of novel subtypes of acute lymphoblastic leukemia in the context of minimal residual disease-directed therapy. Blood Cancer Discov. 2021;2(4):326-337doi: 10.1158/2643-3230.bcd-20-0229.
Jeha, S., Choi, J., Roberts, K. G., Pei, D., Coustan-Smith, E., Inaba, H., Rubnitz, J. E., Ribeiro, R. C., Gruber, T. A., Raimondi, S. C., Karol, S. E., Qu, C., Brady, S. W., Gu, Z., Yang, J. J., Cheng, C., Downing, J. R., Evans, W. E., Relling, M. V., Campana, D., Mullighan, C. G., & Pui, C. H. (2021). Clinical significance of novel subtypes of acute lymphoblastic leukemia in the context of minimal residual disease-directed therapy. Blood cancer discovery, 2(4), 326-337. https://doi.org/10.1158/2643-3230.bcd-20-0229
Jeha, Sima, et al. "Clinical significance of novel subtypes of acute lymphoblastic leukemia in the context of minimal residual disease-directed therapy." Blood cancer discovery vol. 2,4 (2021): 326-337. doi: https://doi.org/10.1158/2643-3230.bcd-20-0229
Jeha S, Choi J, Roberts KG, Pei D, Coustan-Smith E, Inaba H, Rubnitz JE, Ribeiro RC, Gruber TA, Raimondi SC, Karol SE, Qu C, Brady SW, Gu Z, Yang JJ, Cheng C, Downing JR, Evans WE, Relling MV, Campana D, Mullighan CG, Pui CH. Clinical significance of novel subtypes of acute lymphoblastic leukemia in the context of minimal residual disease-directed therapy. Blood Cancer Discov. 2021 Jul;2(4):326-337. doi: 10.1158/2643-3230.bcd-20-0229. PMID: 34250504; PMCID: PMC8265990.
Copy Download .nbib Format: NLM
New insights into methotrexate accumulation in leukemia cells .

Molecular & cellular oncology

Lopez-Lopez E, Evans WE.
PMID: 33553612
Mol Cell Oncol. 2021 Jan 11;8(1):1865086. doi: 10.1080/23723556.2020.1865086. eCollection 2021.

Measuring the amount of methotrexate polyglutamates (MTXPG) in leukemia cells after high-dose methotrexate (HDMTX) revealed that molecular subtype and lineage of acute lymphoblastic leukemia (ALL), the ratio of expression of folate influx and efflux transporters, methotrexate (MTX) infusion time,...

Cite
Lopez-Lopez E, Evans WE. New insights into methotrexate accumulation in leukemia cells . Mol Cell Oncol. 2021;8(1):1865086doi: 10.1080/23723556.2020.1865086.
Lopez-Lopez, E., & Evans, W. E. (2021). New insights into methotrexate accumulation in leukemia cells . Molecular & cellular oncology, 8(1), 1865086. https://doi.org/10.1080/23723556.2020.1865086
Lopez-Lopez, Elixabet, and Evans, William E. "New insights into methotrexate accumulation in leukemia cells ." Molecular & cellular oncology vol. 8,1 (2021): 1865086. doi: https://doi.org/10.1080/23723556.2020.1865086
Lopez-Lopez E, Evans WE. New insights into methotrexate accumulation in leukemia cells . Mol Cell Oncol. 2021 Jan 11;8(1):1865086. doi: 10.1080/23723556.2020.1865086. eCollection 2021. PMID: 33553612; PMCID: PMC7849719.
Copy Download .nbib Format: NLM
New insights into methotrexate accumulation in leukemia cells .

Molecular & cellular oncology

Lopez-Lopez E, Evans WE.
PMID: 33553612
Mol Cell Oncol. 2021 Jan 11;8(1):1865086. doi: 10.1080/23723556.2020.1865086. eCollection 2021.

Measuring the amount of methotrexate polyglutamates (MTXPG) in leukemia cells after high-dose methotrexate (HDMTX) revealed that molecular subtype and lineage of acute lymphoblastic leukemia (ALL), the ratio of expression of folate influx and efflux transporters, methotrexate (MTX) infusion time,...

Cite
Lopez-Lopez E, Evans WE. New insights into methotrexate accumulation in leukemia cells . Mol Cell Oncol. 2021;8(1):1865086doi: 10.1080/23723556.2020.1865086.
Lopez-Lopez, E., & Evans, W. E. (2021). New insights into methotrexate accumulation in leukemia cells . Molecular & cellular oncology, 8(1), 1865086. https://doi.org/10.1080/23723556.2020.1865086
Lopez-Lopez, Elixabet, and Evans, William E. "New insights into methotrexate accumulation in leukemia cells ." Molecular & cellular oncology vol. 8,1 (2021): 1865086. doi: https://doi.org/10.1080/23723556.2020.1865086
Lopez-Lopez E, Evans WE. New insights into methotrexate accumulation in leukemia cells . Mol Cell Oncol. 2021 Jan 11;8(1):1865086. doi: 10.1080/23723556.2020.1865086. eCollection 2021. PMID: 33553612; PMCID: PMC7849719.
Copy Download .nbib Format: NLM
Population Pharmacokinetics of Vincristine Related to Infusion Duration and Peripheral Neuropathy in Pediatric Oncology Patients.

Cancers

van de Velde ME, Panetta JC, Wilhelm AJ, van den Berg MH, van der Sluis IM, van den Bos C, Abbink FCH, van den Heuvel-Eibrink MM, Segers H, Chantrain C, van der Werff Ten Bosch J, Willems L, Evans WE, Kaspers GL.
PMID: 32635465
Cancers (Basel). 2020 Jul 04;12(7). doi: 10.3390/cancers12071789.

Vincristine (VCR) is frequently used in pediatric oncology and can be administered intravenously through push injections or 1 h infusions. The effects of administration duration on population pharmacokinetics (PK) are unknown. We described PK differences related to administration duration...

Cite
van de Velde ME, Panetta JC, Wilhelm AJ, et al. Population Pharmacokinetics of Vincristine Related to Infusion Duration and Peripheral Neuropathy in Pediatric Oncology Patients. Cancers (Basel). 2020;12(7)doi: 10.3390/cancers12071789.
van de Velde, M. E., Panetta, J. C., Wilhelm, A. J., van den Berg, M. H., van der Sluis, I. M., van den Bos, C., Abbink, F. C. H., van den Heuvel-Eibrink, M. M., Segers, H., Chantrain, C., van der Werff Ten Bosch, J., Willems, L., Evans, W. E., & Kaspers, G. L. (2020). Population Pharmacokinetics of Vincristine Related to Infusion Duration and Peripheral Neuropathy in Pediatric Oncology Patients. Cancers, 12(7), . https://doi.org/10.3390/cancers12071789
van de Velde, Mirjam Esther, et al. "Population Pharmacokinetics of Vincristine Related to Infusion Duration and Peripheral Neuropathy in Pediatric Oncology Patients." Cancers vol. 12,7 (2020). doi: https://doi.org/10.3390/cancers12071789
van de Velde ME, Panetta JC, Wilhelm AJ, van den Berg MH, van der Sluis IM, van den Bos C, Abbink FCH, van den Heuvel-Eibrink MM, Segers H, Chantrain C, van der Werff Ten Bosch J, Willems L, Evans WE, Kaspers GL. Population Pharmacokinetics of Vincristine Related to Infusion Duration and Peripheral Neuropathy in Pediatric Oncology Patients. Cancers (Basel). 2020 Jul 04;12(7). doi: 10.3390/cancers12071789. PMID: 32635465; PMCID: PMC7407622.
Copy Download .nbib Format: NLM
Profiling chromatin accessibility in pediatric acute lymphoblastic leukemia identifies subtype-specific chromatin landscapes and gene regulatory networks.

Leukemia

Diedrich JD, Dong Q, Ferguson DC, Bergeron BP, Autry RJ, Qian M, Yang W, Smith C, Papizan JB, Connelly JP, Hagiwara K, Crews KR, Pruett-Miller SM, Pui CH, Yang JJ, Relling MV, Evans WE, Savic D.
PMID: 33714976
Leukemia. 2021 Nov;35(11):3078-3091. doi: 10.1038/s41375-021-01209-1. Epub 2021 Mar 13.

Acute lymphoblastic leukemia (ALL) is a hematopoietic malignancy comprised of molecular subtypes largely characterized by aneuploidy or recurring chromosomal rearrangements. Despite extensive information on the ALL transcriptome and methylome, there is limited understanding of the ALL chromatin landscape. We...

Cite
Diedrich JD, Dong Q, Ferguson DC, et al. Profiling chromatin accessibility in pediatric acute lymphoblastic leukemia identifies subtype-specific chromatin landscapes and gene regulatory networks. Leukemia. 2021;35(11):3078-3091doi: 10.1038/s41375-021-01209-1.
Diedrich, J. D., Dong, Q., Ferguson, D. C., Bergeron, B. P., Autry, R. J., Qian, M., Yang, W., Smith, C., Papizan, J. B., Connelly, J. P., Hagiwara, K., Crews, K. R., Pruett-Miller, S. M., Pui, C. H., Yang, J. J., Relling, M. V., Evans, W. E., & Savic, D. (2021). Profiling chromatin accessibility in pediatric acute lymphoblastic leukemia identifies subtype-specific chromatin landscapes and gene regulatory networks. Leukemia, 35(11), 3078-3091. https://doi.org/10.1038/s41375-021-01209-1
Diedrich, Jonathan D, et al. "Profiling chromatin accessibility in pediatric acute lymphoblastic leukemia identifies subtype-specific chromatin landscapes and gene regulatory networks." Leukemia vol. 35,11 (2021): 3078-3091. doi: https://doi.org/10.1038/s41375-021-01209-1
Diedrich JD, Dong Q, Ferguson DC, Bergeron BP, Autry RJ, Qian M, Yang W, Smith C, Papizan JB, Connelly JP, Hagiwara K, Crews KR, Pruett-Miller SM, Pui CH, Yang JJ, Relling MV, Evans WE, Savic D. Profiling chromatin accessibility in pediatric acute lymphoblastic leukemia identifies subtype-specific chromatin landscapes and gene regulatory networks. Leukemia. 2021 Nov;35(11):3078-3091. doi: 10.1038/s41375-021-01209-1. Epub 2021 Mar 13. PMID: 33714976; PMCID: PMC8435544.
Copy Download .nbib Format: NLM
Profiling chromatin accessibility in pediatric acute lymphoblastic leukemia identifies subtype-specific chromatin landscapes and gene regulatory networks.

Leukemia

Diedrich JD, Dong Q, Ferguson DC, Bergeron BP, Autry RJ, Qian M, Yang W, Smith C, Papizan JB, Connelly JP, Hagiwara K, Crews KR, Pruett-Miller SM, Pui CH, Yang JJ, Relling MV, Evans WE, Savic D.
PMID: 33714976
Leukemia. 2021 Nov;35(11):3078-3091. doi: 10.1038/s41375-021-01209-1. Epub 2021 Mar 13.

Acute lymphoblastic leukemia (ALL) is a hematopoietic malignancy comprised of molecular subtypes largely characterized by aneuploidy or recurring chromosomal rearrangements. Despite extensive information on the ALL transcriptome and methylome, there is limited understanding of the ALL chromatin landscape. We...

Cite
Diedrich JD, Dong Q, Ferguson DC, et al. Profiling chromatin accessibility in pediatric acute lymphoblastic leukemia identifies subtype-specific chromatin landscapes and gene regulatory networks. Leukemia. 2021;35(11):3078-3091doi: 10.1038/s41375-021-01209-1.
Diedrich, J. D., Dong, Q., Ferguson, D. C., Bergeron, B. P., Autry, R. J., Qian, M., Yang, W., Smith, C., Papizan, J. B., Connelly, J. P., Hagiwara, K., Crews, K. R., Pruett-Miller, S. M., Pui, C. H., Yang, J. J., Relling, M. V., Evans, W. E., & Savic, D. (2021). Profiling chromatin accessibility in pediatric acute lymphoblastic leukemia identifies subtype-specific chromatin landscapes and gene regulatory networks. Leukemia, 35(11), 3078-3091. https://doi.org/10.1038/s41375-021-01209-1
Diedrich, Jonathan D, et al. "Profiling chromatin accessibility in pediatric acute lymphoblastic leukemia identifies subtype-specific chromatin landscapes and gene regulatory networks." Leukemia vol. 35,11 (2021): 3078-3091. doi: https://doi.org/10.1038/s41375-021-01209-1
Diedrich JD, Dong Q, Ferguson DC, Bergeron BP, Autry RJ, Qian M, Yang W, Smith C, Papizan JB, Connelly JP, Hagiwara K, Crews KR, Pruett-Miller SM, Pui CH, Yang JJ, Relling MV, Evans WE, Savic D. Profiling chromatin accessibility in pediatric acute lymphoblastic leukemia identifies subtype-specific chromatin landscapes and gene regulatory networks. Leukemia. 2021 Nov;35(11):3078-3091. doi: 10.1038/s41375-021-01209-1. Epub 2021 Mar 13. PMID: 33714976; PMCID: PMC8435544.
Copy Download .nbib Format: NLM
New insights into methotrexate accumulation in leukemia cells .

Molecular & cellular oncology

Lopez-Lopez E, Evans WE.
PMID: 33553612
Mol Cell Oncol. 2021 Jan 11;8(1):1865086. doi: 10.1080/23723556.2020.1865086. eCollection 2021.

Measuring the amount of methotrexate polyglutamates (MTXPG) in leukemia cells after high-dose methotrexate (HDMTX) revealed that molecular subtype and lineage of acute lymphoblastic leukemia (ALL), the ratio of expression of folate influx and efflux transporters, methotrexate (MTX) infusion time,...

Cite
Lopez-Lopez E, Evans WE. New insights into methotrexate accumulation in leukemia cells . Mol Cell Oncol. 2021;8(1):1865086doi: 10.1080/23723556.2020.1865086.
Lopez-Lopez, E., & Evans, W. E. (2021). New insights into methotrexate accumulation in leukemia cells . Molecular & cellular oncology, 8(1), 1865086. https://doi.org/10.1080/23723556.2020.1865086
Lopez-Lopez, Elixabet, and Evans, William E. "New insights into methotrexate accumulation in leukemia cells ." Molecular & cellular oncology vol. 8,1 (2021): 1865086. doi: https://doi.org/10.1080/23723556.2020.1865086
Lopez-Lopez E, Evans WE. New insights into methotrexate accumulation in leukemia cells . Mol Cell Oncol. 2021 Jan 11;8(1):1865086. doi: 10.1080/23723556.2020.1865086. eCollection 2021. PMID: 33553612; PMCID: PMC7849719.
Copy Download .nbib Format: NLM
Mutational landscape and patterns of clonal evolution in relapsed pediatric acute lymphoblastic leukemia.

Blood cancer discovery

Waanders E, Gu Z, Dobson SM, Antić Ž, Crawford JC, Ma X, Edmonson MN, Payne-Turner D, van der Vorst M, Jongmans MCJ, McGuire I, Zhou X, Wang J, Shi L, Pounds S, Pei D, Cheng C, Song G, Fan Y, Shao Y, Rusch M, McCastlain K, Yu J, van Boxtel R, Blokzijl F, Iacobucci I, Roberts KG, Wen J, Wu G, Ma J, Easton J, Neale G, Olsen SR, Nichols KE, Pui CH, Zhang J, Evans WE, Relling MV, Yang JJ, Thomas PG, Dick JE, Kuiper RP, Mullighan CG.
PMID: 32793890
Blood Cancer Discov. 2020 Jul;1(1):96-111. doi: 10.1158/0008-5472.BCD-19-0041.

Relapse of acute lymphoblastic leukemia (ALL) remains a leading cause of childhood death. Prior studies have shown clonal mutations at relapse often arise from relapse-fated subclones that exist at diagnosis. However, the genomic landscape, evolutionary trajectories and mutational mechanisms...

Cite
Waanders E, Gu Z, Dobson SM, et al. Mutational landscape and patterns of clonal evolution in relapsed pediatric acute lymphoblastic leukemia. Blood Cancer Discov. 2020;1(1):96-111doi: 10.1158/0008-5472.BCD-19-0041.
Waanders, E., Gu, Z., Dobson, S. M., Antić, �. �., Crawford, J. C., Ma, X., Edmonson, M. N., Payne-Turner, D., van der Vorst, M., Jongmans, M. C. J., McGuire, I., Zhou, X., Wang, J., Shi, L., Pounds, S., Pei, D., Cheng, C., Song, G., Fan, Y., Shao, Y., Rusch, M., McCastlain, K., Yu, J., van Boxtel, R., Blokzijl, F., Iacobucci, I., Roberts, K. G., Wen, J., Wu, G., Ma, J., Easton, J., Neale, G., Olsen, S. R., Nichols, K. E., Pui, C. H., Zhang, J., Evans, W. E., Relling, M. V., Yang, J. J., Thomas, P. G., Dick, J. E., Kuiper, R. P., & Mullighan, C. G. (2020). Mutational landscape and patterns of clonal evolution in relapsed pediatric acute lymphoblastic leukemia. Blood cancer discovery, 1(1), 96-111. https://doi.org/10.1158/0008-5472.BCD-19-0041
Waanders, Esmé, et al. "Mutational landscape and patterns of clonal evolution in relapsed pediatric acute lymphoblastic leukemia." Blood cancer discovery vol. 1,1 (2020): 96-111. doi: https://doi.org/10.1158/0008-5472.BCD-19-0041
Waanders E, Gu Z, Dobson SM, Antić Ž, Crawford JC, Ma X, Edmonson MN, Payne-Turner D, van der Vorst M, Jongmans MCJ, McGuire I, Zhou X, Wang J, Shi L, Pounds S, Pei D, Cheng C, Song G, Fan Y, Shao Y, Rusch M, McCastlain K, Yu J, van Boxtel R, Blokzijl F, Iacobucci I, Roberts KG, Wen J, Wu G, Ma J, Easton J, Neale G, Olsen SR, Nichols KE, Pui CH, Zhang J, Evans WE, Relling MV, Yang JJ, Thomas PG, Dick JE, Kuiper RP, Mullighan CG. Mutational landscape and patterns of clonal evolution in relapsed pediatric acute lymphoblastic leukemia. Blood Cancer Discov. 2020 Jul;1(1):96-111. doi: 10.1158/0008-5472.BCD-19-0041. PMID: 32793890; PMCID: PMC7418874.
Copy Download .nbib Format: NLM
Pharmacogenomics of adverse effects of anti-leukemic agents in children.

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG

Relling MV.
PMID: 23118655
J Pediatr Pharmacol Ther. 2012 Jan;17(1):7-11. doi: 10.5863/1551-6776-17.1.7.

No abstract available.

Cite
Relling MV. Pharmacogenomics of adverse effects of anti-leukemic agents in children. J Pediatr Pharmacol Ther. 2012;17(1):7-11doi: 10.5863/1551-6776-17.1.7.
Relling, M. V. (2012). Pharmacogenomics of adverse effects of anti-leukemic agents in children. The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG, 17(1), 7-11. https://doi.org/10.5863/1551-6776-17.1.7
Relling, Mary V. "Pharmacogenomics of adverse effects of anti-leukemic agents in children." The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG vol. 17,1 (2012): 7-11. doi: https://doi.org/10.5863/1551-6776-17.1.7
Relling MV. Pharmacogenomics of adverse effects of anti-leukemic agents in children. J Pediatr Pharmacol Ther. 2012 Jan;17(1):7-11. doi: 10.5863/1551-6776-17.1.7. PMID: 23118655; PMCID: PMC3428190.
Copy Download .nbib Format: NLM
Integrative genomic analyses reveal mechanisms of glucocorticoid resistance in acute lymphoblastic leukemia.

Nature cancer

Autry RJ, Paugh SW, Carter R, Shi L, Liu J, Ferguson DC, Lau CE, Bonten EJ, Yang W, McCorkle JR, Beard JA, Panetta JC, Diedrich JD, Crews KR, Pei D, Coke CJ, Natarajan S, Khatamian A, Karol SE, Lopez-Lopez E, Diouf B, Smith C, Gocho Y, Hagiwara K, Roberts KG, Pounds S, Kornblau SM, Stock W, Paietta EM, Litzow MR, Inaba H, Mullighan CG, Jeha S, Pui CH, Cheng C, Savic D, Yu J, Gawad C, Relling MV, Yang JJ, Evans WE.
PMID: 32885175
Nat Cancer. 2020 Mar;1(3):329-344. doi: 10.1038/s43018-020-0037-3. Epub 2020 Mar 09.

Identification of genomic and epigenomic determinants of drug resistance provides important insights for improving cancer treatment. Using agnostic genome-wide interrogation of mRNA and miRNA expression, DNA methylation, SNPs, CNAs and SNVs/Indels in primary human acute lymphoblastic leukemia cells, we...

Cite
Autry RJ, Paugh SW, Carter R, et al. Integrative genomic analyses reveal mechanisms of glucocorticoid resistance in acute lymphoblastic leukemia. Nat Cancer. 2020;1(3):329-344doi: 10.1038/s43018-020-0037-3.
Autry, R. J., Paugh, S. W., Carter, R., Shi, L., Liu, J., Ferguson, D. C., Lau, C. E., Bonten, E. J., Yang, W., McCorkle, J. R., Beard, J. A., Panetta, J. C., Diedrich, J. D., Crews, K. R., Pei, D., Coke, C. J., Natarajan, S., Khatamian, A., Karol, S. E., Lopez-Lopez, E., Diouf, B., Smith, C., Gocho, Y., Hagiwara, K., Roberts, K. G., Pounds, S., Kornblau, S. M., Stock, W., Paietta, E. M., Litzow, M. R., Inaba, H., Mullighan, C. G., Jeha, S., Pui, C. H., Cheng, C., Savic, D., Yu, J., Gawad, C., Relling, M. V., Yang, J. J., & Evans, W. E. (2020). Integrative genomic analyses reveal mechanisms of glucocorticoid resistance in acute lymphoblastic leukemia. Nature cancer, 1(3), 329-344. https://doi.org/10.1038/s43018-020-0037-3
Autry, Robert J, et al. "Integrative genomic analyses reveal mechanisms of glucocorticoid resistance in acute lymphoblastic leukemia." Nature cancer vol. 1,3 (2020): 329-344. doi: https://doi.org/10.1038/s43018-020-0037-3
Autry RJ, Paugh SW, Carter R, Shi L, Liu J, Ferguson DC, Lau CE, Bonten EJ, Yang W, McCorkle JR, Beard JA, Panetta JC, Diedrich JD, Crews KR, Pei D, Coke CJ, Natarajan S, Khatamian A, Karol SE, Lopez-Lopez E, Diouf B, Smith C, Gocho Y, Hagiwara K, Roberts KG, Pounds S, Kornblau SM, Stock W, Paietta EM, Litzow MR, Inaba H, Mullighan CG, Jeha S, Pui CH, Cheng C, Savic D, Yu J, Gawad C, Relling MV, Yang JJ, Evans WE. Integrative genomic analyses reveal mechanisms of glucocorticoid resistance in acute lymphoblastic leukemia. Nat Cancer. 2020 Mar;1(3):329-344. doi: 10.1038/s43018-020-0037-3. Epub 2020 Mar 09. PMID: 32885175; PMCID: PMC7467080.
Copy Download .nbib Format: NLM
Clinical significance of novel subtypes of acute lymphoblastic leukemia in the context of minimal residual disease-directed therapy.

Blood cancer discovery

Jeha S, Choi J, Roberts KG, Pei D, Coustan-Smith E, Inaba H, Rubnitz JE, Ribeiro RC, Gruber TA, Raimondi SC, Karol SE, Qu C, Brady SW, Gu Z, Yang JJ, Cheng C, Downing JR, Evans WE, Relling MV, Campana D, Mullighan CG, Pui CH.
PMID: 34250504
Blood Cancer Discov. 2021 Jul;2(4):326-337. doi: 10.1158/2643-3230.BCD-20-0229.

We evaluate clinical significance of recently identified subtypes of acute lymphoblastic leukemia (ALL) in 598 children treated with minimal residual disease (MRD)-directed therapy. Among the 16 B-ALL and 8 T-ALL subtypes identified by next generation sequencing,

Cite
Jeha S, Choi J, Roberts KG, et al. Clinical significance of novel subtypes of acute lymphoblastic leukemia in the context of minimal residual disease-directed therapy. Blood Cancer Discov. 2021;2(4):326-337doi: 10.1158/2643-3230.BCD-20-0229.
Jeha, S., Choi, J., Roberts, K. G., Pei, D., Coustan-Smith, E., Inaba, H., Rubnitz, J. E., Ribeiro, R. C., Gruber, T. A., Raimondi, S. C., Karol, S. E., Qu, C., Brady, S. W., Gu, Z., Yang, J. J., Cheng, C., Downing, J. R., Evans, W. E., Relling, M. V., Campana, D., Mullighan, C. G., & Pui, C. H. (2021). Clinical significance of novel subtypes of acute lymphoblastic leukemia in the context of minimal residual disease-directed therapy. Blood cancer discovery, 2(4), 326-337. https://doi.org/10.1158/2643-3230.BCD-20-0229
Jeha, Sima, et al. "Clinical significance of novel subtypes of acute lymphoblastic leukemia in the context of minimal residual disease-directed therapy." Blood cancer discovery vol. 2,4 (2021): 326-337. doi: https://doi.org/10.1158/2643-3230.BCD-20-0229
Jeha S, Choi J, Roberts KG, Pei D, Coustan-Smith E, Inaba H, Rubnitz JE, Ribeiro RC, Gruber TA, Raimondi SC, Karol SE, Qu C, Brady SW, Gu Z, Yang JJ, Cheng C, Downing JR, Evans WE, Relling MV, Campana D, Mullighan CG, Pui CH. Clinical significance of novel subtypes of acute lymphoblastic leukemia in the context of minimal residual disease-directed therapy. Blood Cancer Discov. 2021 Jul;2(4):326-337. doi: 10.1158/2643-3230.BCD-20-0229. PMID: 34250504; PMCID: PMC8265990.
Copy Download .nbib Format: NLM
Integrative genomic analyses reveal mechanisms of glucocorticoid resistance in acute lymphoblastic leukemia.

Nature cancer

Autry RJ, Paugh SW, Carter R, Shi L, Liu J, Ferguson DC, Lau CE, Bonten EJ, Yang W, McCorkle JR, Beard JA, Panetta JC, Diedrich JD, Crews KR, Pei D, Coke CJ, Natarajan S, Khatamian A, Karol SE, Lopez-Lopez E, Diouf B, Smith C, Gocho Y, Hagiwara K, Roberts KG, Pounds S, Kornblau SM, Stock W, Paietta EM, Litzow MR, Inaba H, Mullighan CG, Jeha S, Pui CH, Cheng C, Savic D, Yu J, Gawad C, Relling MV, Yang JJ, Evans WE.
PMID: 32885175
Nat Cancer. 2020 Mar;1(3):329-344. doi: 10.1038/s43018-020-0037-3. Epub 2020 Mar 09.

Identification of genomic and epigenomic determinants of drug resistance provides important insights for improving cancer treatment. Using agnostic genome-wide interrogation of mRNA and miRNA expression, DNA methylation, SNPs, CNAs and SNVs/Indels in primary human acute lymphoblastic leukemia cells, we...

Cite
Autry RJ, Paugh SW, Carter R, et al. Integrative genomic analyses reveal mechanisms of glucocorticoid resistance in acute lymphoblastic leukemia. Nat Cancer. 2020;1(3):329-344doi: 10.1038/s43018-020-0037-3.
Autry, R. J., Paugh, S. W., Carter, R., Shi, L., Liu, J., Ferguson, D. C., Lau, C. E., Bonten, E. J., Yang, W., McCorkle, J. R., Beard, J. A., Panetta, J. C., Diedrich, J. D., Crews, K. R., Pei, D., Coke, C. J., Natarajan, S., Khatamian, A., Karol, S. E., Lopez-Lopez, E., Diouf, B., Smith, C., Gocho, Y., Hagiwara, K., Roberts, K. G., Pounds, S., Kornblau, S. M., Stock, W., Paietta, E. M., Litzow, M. R., Inaba, H., Mullighan, C. G., Jeha, S., Pui, C. H., Cheng, C., Savic, D., Yu, J., Gawad, C., Relling, M. V., Yang, J. J., & Evans, W. E. (2020). Integrative genomic analyses reveal mechanisms of glucocorticoid resistance in acute lymphoblastic leukemia. Nature cancer, 1(3), 329-344. https://doi.org/10.1038/s43018-020-0037-3
Autry, Robert J, et al. "Integrative genomic analyses reveal mechanisms of glucocorticoid resistance in acute lymphoblastic leukemia." Nature cancer vol. 1,3 (2020): 329-344. doi: https://doi.org/10.1038/s43018-020-0037-3
Autry RJ, Paugh SW, Carter R, Shi L, Liu J, Ferguson DC, Lau CE, Bonten EJ, Yang W, McCorkle JR, Beard JA, Panetta JC, Diedrich JD, Crews KR, Pei D, Coke CJ, Natarajan S, Khatamian A, Karol SE, Lopez-Lopez E, Diouf B, Smith C, Gocho Y, Hagiwara K, Roberts KG, Pounds S, Kornblau SM, Stock W, Paietta EM, Litzow MR, Inaba H, Mullighan CG, Jeha S, Pui CH, Cheng C, Savic D, Yu J, Gawad C, Relling MV, Yang JJ, Evans WE. Integrative genomic analyses reveal mechanisms of glucocorticoid resistance in acute lymphoblastic leukemia. Nat Cancer. 2020 Mar;1(3):329-344. doi: 10.1038/s43018-020-0037-3. Epub 2020 Mar 09. PMID: 32885175; PMCID: PMC7467080.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 13 entries